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thyrotropin (TSH) and free thyroxine (FT4) were measured 
at 12, 20 and 35 weeks and thyroglobulin antibodies (Tg-
Ab) at 12 weeks.
Results 93.5 % of participants completed the study. 
Se supplementation had no more effect than placebo in 
decreasing TPO-Ab concentration or the prevalence of 
TPO-Ab positivity during the course of pregnancy. In 
women who were either TPO-Ab or Tg-Ab negative at 
baseline (Thy-Ab−ve), TSH increased and FT4 decreased 
significantly throughout gestation (P < 0.001), with no dif-
ference between treatment groups. In women who were 
Thy-Ab+ve at baseline, TSH tended to decrease and was 
lower than placebo at 35 weeks (P = 0.050). FT4 fell more 
on Se than placebo supplementation and was significantly 
lower at 35 weeks (P = 0.029).
Conclusions Low-dose selenium supplementation in 
pregnant women with mild-to-moderate deficiency had no 
effect on TPO-Ab concentration, but tended to change thy-
roid function in Thy-Ab+ve women.
Keywords Selenium · Iodine · Pregnancy · Thyroid 
autoimmunity · Thyroid peroxidase antibodies · Thyroid 
function
Introduction
Selenium (Se) is an essential trace element, which carries 
out its nutritional functions through the selenoproteins, 25 
of which have been identified in humans [1]. Se is impor-
tant for human health and affects immune and thyroid func-
tion [2]. The thyroid has the highest Se concentration of 
all tissues indicating its importance to that organ. It con-
tains many selenoproteins including the deiodinases (Dio), 
the glutathione peroxidases, the thioredoxin reductases, 
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component of selenoproteins that are involved in the pro-
duction of thyroid hormones and in regulating the immune 
response. We aimed to explore the effect of low-dose sele-
nium supplementation on thyroid peroxidase antibody 
(TPO-Ab) concentration and thyroid function in preg-
nant women from a mild-to-moderate iodine-deficient 
population.
Methods Samples and data were from a secondary analy-
sis of Selenium in PRegnancy INTervention (SPRINT), a 
double-blind, randomized, placebo-controlled study that 
recruited 230 women with singleton pregnancies from a 
UK antenatal clinic at 12 weeks of gestation. Women were 
randomized to receive 60 µg/day selenium or placebo until 
delivery. Serum thyroid peroxidase antibodies (TPO-Ab), 
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selenoprotein P (SEPP1) and selenoprotein S; these are 
involved in regulating thyroid hormone metabolism and 
redox status [3].
The presence of thyroid autoantibodies to thyroid per-
oxidase (TPO-Ab) and thyroglobulin (Tg-Ab) is common 
in women of reproductive age and is indicative of thyroid 
inflammation and an increased risk of developing autoim-
mune thyroid disease, such as Hashimoto’s thyroiditis [4]. 
TPO-Ab positivity in euthyroid women is associated with 
a series of fetomaternal complications such as miscarriage, 
preterm delivery, postpartum thyroid dysfunction and even 
impaired neuropsychological development in the offspring 
[5–7]. In recent years, a number of studies have reported 
that Se supplementation decreased the concentration of 
TPO-Ab, but not all studies have shown benefit [8]. Con-
siderable heterogeneity occurred among these studies with 
respect to age, gender, Se dose, baseline Se and iodine sta-
tus, TPO-Ab concentration, thyroid function and whether 
the thyroid hormone, levothyroxine (LT4), was simultane-
ously administered. To date, only one study has been car-
ried out in pregnant women; that study showed that Se sup-
plementation during pregnancy and the postpartum period 
reduced TPO-Ab concentration, the incidence of postpar-
tum thyroid dysfunction and permanent hypothyroidism 
[7]. Unfortunately, that study did not measure iodine sta-
tus, which is crucial for thyroid function and may influence 
the effect of Se on the thyroid [9]. Several studies have 
reported that pregnant women in the UK are iodine defi-
cient [10–12]. Normal thyroid function during pregnancy 
is important for a healthy pregnancy and fetal neurological 
development [13].
We had the opportunity to investigate the effect of a 
nutritional dose of Se on TPO-Ab concentration and thy-
roid function in pregnancy by using stored samples from 
the Se in PRegnancy INTervention (SPRINT) study in 
which iodine status was also measured [14, 15].
Subjects and methods
Participants
The SPRINT study [14] was a double-blind, randomized, 
placebo-controlled, single-center study (Registration no. 
ISRCTN37927591). It was conducted in accordance with 
the guidelines of the Declaration of Helsinki. All proce-
dures involving human subjects were approved by the Mil-
ton Keynes Research Ethics Committee (REC reference 
no. 08/H0603/46). Written informed consent was obtained 
from all subjects.
Two hundred and thirty women in their first pregnancy 
were recruited at 12–14 weeks and randomized to receive 
60 µg/day Se (as Se-yeast) or placebo-yeast until delivery. 
Blood samples were collected at 12 (baseline), 20 and 35 
gestational weeks. Serum was prepared, and samples were 
stored at –80 °C until analyzed. One woman, recruited in 
error, was excluded from the analysis, leaving 114 women 
in the placebo group and 115 women in the Se group.
Laboratory analyses
Whole-blood Se concentration at 12 and 35 weeks and uri-
nary iodine concentration (UIC) at 12 weeks were meas-
ured by dynamic reaction cell inductively coupled plasma 
mass (SCIEX Perkin-Elmer, Beaconsfield, UK) [14, 16]. 
Urinary creatinine was measured by the Jaffe rate method, 
and individual iodine status was expressed as the iodine-to-
creatinine ratio as previously reported [16]. Plasma SEPP1 
concentration at 35 weeks was measured by ELISA [14, 
17].
Serum thyroid-stimulating hormone (TSH), free thy-
roxine (FT4) and TPO-Ab at 12, 20 and 35 weeks were 
measured with commercial kits on Modular Analytics E170 
(Roche Diagnostics, Germany); serum Tg-Ab at baseline 
was measured using the Cobas e601 analyzer (Roche Diag-
nostics, Germany). Inter- and intra-assay coefficients of 
variation for all measurements were less than 5 %. Thyroid 
dysfunction was assessed by trimester-specific reference 
ranges as established by Stricker et al. [18]. The criteria 
for various thyroid dysfunctions were defined as shown in 
Table 1.
Statistical analysis
Categorical variables between the two groups were ana-
lyzed with the Chi-squared test or Fisher’s exact test. 
The prevalence of TPO-Ab positivity within each group 
was analyzed by Cochran’s Q test. Continuous variables 
(whole-blood Se, plasma SEPP1, iodine-to-creatinine ratio 
and TPO-Ab concentration) with skewed distributions were 
analyzed by the Mann–Whitney U test between groups. 
Within groups, the Wilcoxon matched-pairs test was used.
As TSH was not normally distributed and included val-
ues between 0 and 1, a constant of 1 was added to the val-
ues that were then log-transformed (Log-TSH) to achieve 
normality; TSH values were reported as geometric means 
and 95 % confidence intervals (CIs) by back-transforma-
tion into the original units. Continuous variables (Log-TSH 
and FT4) with normal distribution were analyzed within 
subjects by a paired t test. A General Linear Model was 
used for comparison of Log-TSH and FT4 between groups, 
controlling for several covariates (continuous) at baseline, 
including age, gestational age at recruitment, BMI, log-
transformed whole-blood Se (Log-Se) and log-transformed 
iodine-to-creatinine ratio (Log-Iodine). When exploring the 
effect of Se versus placebo on Log-TSH or FT4 at 20 and 
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35 weeks, baseline Log-TSH or FT4 was also added into 
the model as covariates, respectively.
Statistics were conducted using IBM SPSS statistics ver-
sion 20. Tests of significance were two-tailed, and statisti-
cal significance was set at P < 0.05.
Results
Se status at baseline and after Se supplementation 
and iodine status at baseline
At baseline, whole-blood Se [median (IQR)] did not differ 
between Se and placebo groups [1.31 (1.19–1.46) vs. 1.32 
(1.16–1.47) µmol/l, P = 0.565] either in the whole popu-
lation [14], or in Thy-Ab−ve women [1.31 (1.18–1.46) vs. 
1.33 (1.15–1.48) µmol/l, P = 0.920] or Thy-Ab+ve women, 
[1.32 (1.26–1.61) vs. 1.29 (1.15–1.44) µmol/l, P = 0.157]. 
At 35 weeks, whole-blood Se in the Se group was signifi-
cantly higher than in the placebo group [1.87 (1.68–2.15) 
vs. 1.16 (1.05-1.30) µmol/l, P < 0.001], as was SEPP1 [5.30 
(4.58–5.90) vs. 3.00 (2.30–3.60) mg/l, P < 0.001] [14].
At baseline, in the whole population, median (IQR) UIC 
was 42.0 (24.5-84.8) μg/l and median (IQR) iodine-to-cre-
atinine ratio was 102.5 (67.3–166.8) μg/g. Iodine-to-cre-
atinine ratio in the Se group was significantly lower than in 
the placebo group [92.5 (62.8–161.3) vs. 116.0 (75.5–182.0) 
μg/g, P = 0.049]. However, this significant difference only 
occurred in Thy-Ab−ve women [94.0 (63.0–158.0) vs. 117.0 
(73.25–190.25) μg/g, P = 0.034], not in Thy-Ab+ve women 
[86.0 (62.3–179.8) vs. 97.5 (75.5–141.8) μg/g, P = 0.972].
TPO-Ab concentration at baseline and after Se 
supplementation
At baseline, 25 (11.0 %) women were TPO-Ab+ve with a 
median (IQR) TPO-Ab concentration of 110 (60–220) 
kU/l. In TPO-Ab+ve women, TPO-Ab concentration at 
baseline was similar in the Se and placebo groups [120 
(65–203) vs. 110 (57–230) kU/l, P = 0.89]. Though TPO-
Ab concentration decreased over the course of gestation 
(P < 0.001), there was no difference in the magnitude of 
decrease between Se and placebo groups (54.2 vs. 65.6 %, 
P = 0.785), nor in the prevalence of TPO-Ab positivity at 
any gestational week (Table 2).
Prevalence of thyroid dysfunctions at baseline and after Se 
supplementation
One woman had overt hyperthyroidism and two had sub-
clinical hyperthyroidism on recruitment, but none of these 
conditions was apparent by 20 and 35 weeks. There was no 
case of overt hypothyroidism. The prevalence of subclinical 
hypothyroidism (SCH) and hypothyroxinemia is shown in 
Table 1  Criteria for diagnosis of various thyroid dysfunctions in each trimester










2.5–97.5 percentile of  
reference population
TSH (mU/l) 0.07–2.82 0.33–2.89 0.32–2.94
FT4 (pmol/l) 10.48–18.49 9.4–14.06 8.5–13.54
Overt hyperthyroidism TSH below reference  
range and FT4 above
TSH (mU/l) <0.07 <0.33 <0.32
FT4 (pmol/l) >18.49 >14.06 >13.54
Subclinical  
hyperthyroidism
TSH below reference  
range and normal FT4
TSH (mU/l) <0.07 <0.33 <0.32
FT4 (pmol/l) 10.48–18.49 9.4–14.06 8.5–13.54
Overt hypothyroidism TSH above reference  
range and FT4 below
TSH (mU/l) >2.82 >2.89 >2.94
FT4 (pmol/l) <10.48 <9.4 <8.5
Subclinical  
hypothyroidism
TSH above reference  
range and normal FT4
TSH (mU/l) >2.82 >2.89 >2.94
FT4 (pmol/l) 10.48–18.49 9.4–14.06 8.5–13.54
Isolated hypothyroxinemia Normal TSH; FT4 below  
the lowest 10 percentile of  
reference population
TSH (mU/l) 0.07–2.82 0.33–2.89 0.32–2.94
FT4 (pmol/l) <11.43 <9.97 <9.42
TPO-Ab positivity  
(TPO-Ab+ve)
TPO-Ab above cutoff value TPO-Ab (kU/l) ≥35 ≥35 ≥35
Substantially elevated  
TPO-Ab positivity
TPO-Ab above cutoff value TPO-Ab (kU/l) ≥100 ≥100 ≥100
Tg-Ab positivity  
(Tg-Ab+ve)
Tg-Ab above cutoff value Tg-Ab (kU/l) >115 – –
Thyroid antibody positivity 
(Thy-Ab+ve)
Either TPO-Ab positivity  
or Tg-Ab positivity
Either TPO-Ab ≥ 35 kU/l  
or Tg-Ab > 115 kU/l
– –
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Table 2 and did not differ significantly between Se and pla-
cebo groups at any gestational week.
Effect of Se supplementation on thyroid function
TSH at 12 weeks in Thy-Ab+ve women was significantly 
higher than in Thy-Ab−ve women [2.53 (2.12–2.98) vs. 
1.30 (1.19–1.40) mU/l, P < 0.001], and FT4 was signifi-
cantly lower [14.59 (14.20–14.97) vs. 15.15 (14.90–15.41) 
pmol/l, P = 0.016]. As thyroid antibodies influence thyroid 
function [19], the effect of Se supplementation on thyroid 
function was explored separately in Thy-Ab−ve and Thy-
Ab+ve women (Table 3). At 12 weeks, TSH and FT4 did 
not differ between the Se and placebo groups in either Thy-
Ab−ve or Thy-Ab+ve women.
In Thy-Ab−ve women, TSH significantly increased dur-
ing pregnancy in both Se and placebo groups (P < 0.001), 
with no difference between groups. By contrast, in Thy-
Ab+ve women on placebo, TSH decreased slightly from 12 to 
20 weeks with a minor increase toward the end of gestation to 
give a level almost identical to that at 12 weeks (P = 0.900), 
though with a much narrower confidence interval (95 % CI 
range at 35 weeks, 2.24–2.79 vs. 1.89–3.13 at 12 weeks). In 
Thy-Ab+ve women on Se, there was a gradual nonsignifi-
cant (P = 0.310) decrease in TSH that continued until term 
at which time it became almost significantly lower than in 
Thy-Ab+ve women on placebo, after adjustment for baseline 
covariates (P = 0.050). Throughout gestation, TSH was signif-
icantly higher in Thy-Ab+ve than in Thy-Ab−ve women in both 
placebo and Se groups (all P < 0.01 at 12, 20 and 35 weeks).
In Thy-Ab−ve women, FT4 decreased significantly from 
12 to 35 weeks (P < 0.001), and the percentage drop was 
similar in both groups: 26.4 and 25.1 % in placebo and Se 
groups, respectively (P = 0.289). In Thy-Ab+ve women, 
FT4 also fell significantly (P < 0.001), but the drop in mag-
nitude in the placebo group was less than in the Se group 
(19.3 vs. 27.7 %, P = 0.012), resulting in FT4 at 35 weeks 
being significantly lower in the Se group (P = 0.029) after 
adjustment for baseline covariates.
We tested all two-way interactions between the treat-
ment and confounders, including baseline iodine status 
(with outcome of Log-TSH and FT4 as the dependent vari-
able); these were null (data not shown).
Discussion
This is the first paper to explore the effect of a nutritional 
dose of Se on thyroid autoimmunity and thyroid function in 
pregnant women with mild-to-moderate iodine deficiency 
(based on WHO criteria [20]). We found that Se supple-
mentation was no more beneficial than placebo in reducing 
TPO-Ab concentration, though it tended to influence thy-
roid function in Thy-Ab+ve women.
Table 2  Prevalence of thyroid dysfunctions in placebo and Se groups at different weeks of gestation
a P values were from Chi-square test or Fisher’s exact test to compare placebo group versus Se group
Gestational week Placebo group Se group P valuea
No. in group No. with dysfunction n (%) No. in group No. with dysfunction n (%)
Tg-Ab > 115 kU/l
 12 weeks 110 11 (10) 113 11 (9.7) 0.947
TPO-Ab ≥ 35 kU/l
 12 weeks 113 15 (13.3) 115 10 (8.7) 0.269
 20 weeks 112 12 (10.7) 109 8 (7.3) 0.382
 35 weeks 109 7 (6.4) 105 6 (5.7) 0.828
TPO-Ab ≥ 100 kU/l
 12 weeks 113 8 (7.1) 115 6 (5.2) 0.757
 20 weeks 112 7 (6.3) 109 3 (2.8) 0.333
 35 weeks 109 3 (2.8) 105 0 (0) 0.247
Subclinical hypothyroidism
 12 weeks 113 12 (10.6) 115 10 (8.7) 0.623
 20 weeks 112 13 (11.6) 108 7 (6.5) 0.186
 35 weeks 109 13 (11.9) 106 16 (15.1) 0.479
Isolated hypothyroxinemia
 12 weeks 113 1 (0.9) 115 2 (1.7) 1.000
 20 weeks 112 2 (1.8) 108 3 (2.8) 0.679
 35 weeks 109 10 (9.2) 106 10 (9.4) 0.948
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The prevalence of TPO-Ab positivity in our population 
is similar to that reported in previous studies of women of 
childbearing age [6]. However, in contrast to the reduc-
tion in TPO-Ab concentration in Thy-Ab+ve pregnant 
women on supplementation with Se found by Negro et al. 
[7], we found no such effect. There are a number of plau-
sible reasons for the difference between two studies: (1) 
we only had 25, as opposed to 151, TPO-Ab+ve women; 
thus, we had much less chance of seeing an effect; (2) the 
median baseline TPO-Ab concentration in our women was 
much lower: 110 versus 600 kU/l—a higher concentration 
appears to respond better to treatment [21]; (3) the dose 
we gave was much lower: 60 versus 200 μg/d; given the 
substantial fall (12 %) in blood Se in the placebo group in 
this trial from 12 to 35 weeks, which is likely due to the 
uptake of Se (as selenoprotein P) by placental receptors 
combined with an increase in plasma volume [14, 22], our 
Se dose was probably too low to sustain an effect; (4) none 
of our study participants received LT4 treatment in contrast 
to some 20 % of the TPO-Ab+ve women in Negro’s study; 
as LT4 has an additive effect with Se in reducing TPO-
Ab concentration in patients with Hashimoto’s thyroiditis 
(an autoimmune hypothyroid condition) [23], it may have 
helped reduce the TPO-Ab concentration in a percentage of 
those women.
The effects of Se supplementation on TSH and FT4 
differ somewhat between women with and without thy-
roid antibodies. In our Thy-Ab−ve women, the significant 
Table 3  Thyroid function during gestation in the placebo and Se groups
a Unadjusted value of TSH was expressed as median (minimum, maximum) and FT4 as mean (standard deviation)
b Adjusted value of TSH was expressed as geometric mean (95 % CI) and FT4 as mean (95 % CI) with adjustment for the effect of covariates
c P values were from General Linear Model comparing placebo and Se groups adjusted for covariates at baseline, including age, gestational age 
at recruitment, BMI, Log-Se, Log-Iodine and corresponding thyroid parameters, i.e., Log-TSH or FT4
d P values were from paired t test comparing 12 to 35 weeks in each treatment group
Gestational week Placebo group Se group P valuec
n Unadjusted 
valuea





 12 weeks 95 1.30 (0.01, 
4.20)
1.27 (1.12, 1.42) 98 1.30 (0.16, 
4.00)
1.33 (1.19, 1.48) 0.567
 20 weeks 93 1.63 (0.38, 
4.03)
1.66 (1.57, 1.75) 94 1.67 (0.74, 
3.67)
1.65 (1.56, 1.74) 0.897
 35 weeks 91 1.85 (0.38, 
4.98)
1.85 (1.74, 1.98) 90 1.96 (0.45, 
5.35)
1.86 (1.74, 1.99) 0.917
 P valued <0.001 <0.001
FT4 (pmol/l)
 12 weeks 95 15.29 (1.84) 15.30 (14.93, 15.67) 98 15.02 (1.76) 15.01 (14.65, 15.38) 0.256
 20 weeks 93 12.68 (1.38) 12.61 (12.42, 12.81) 94 12.53 (1.51) 12.63 (12.43, 12.82) 0.879
 35 weeks 91 11.19 (1.45) 11.13 (10.90, 11.36) 90 11.15 (1.34) 11.26 (11.03, 11.49) 0.303
 P valued <0.001 <0.001
Thy-Ab+ve women
TSH (mU/l)
 12 weeks 18 2.45 (0.91, 
5.30)
2.46 (1.89, 3.13) 16 2.45 (1.00, 
5.30)
2.61 (1.99, 3.36) 0.754
 20 weeks 18 2.16 (1.08, 
4.26)
2.27 (2.01, 2.55) 13 2.42 (1.43, 
3.95)
2.43 (2.10, 2.78) 0.460
 35 weeks 17 2.39 (1.34, 
4.92)
2.50 (2.24, 2.79) 14 2.28 (1.02, 
5.07)
2.10 (1.83, 2.38) 0.050
 P valued 0.900 0.310
FT4 (pmol/l)
 12 weeks 18 14.33 (1.08) 14.45 (13.87, 14,94) 16 14.88 (1.09) 14.80 (14.23,15.36) 0.334
 20 weeks 18 12.38 (0.94) 12.53 (12.10, 12.96) 13 12.33 (0.96) 12.13 (11.62,12.63) 0.237
 35 weeks 17 11.44 (1.23) 11.67 (11.03, 12.31) 14 10.82 (1.50) 10.54 (9.83, 11.25) 0.029
 P valued <0.001 <0.001
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increase in TSH and decrease in FT4 from 12- to 35-week 
gestation reflect the physiological adaptations of the mater-
nal thyroid during pregnancy and are in line with previous 
findings [24, 25]. The effect of fetal demands, physiological 
rise in T4-binding globulin and increased maternal plasma 
volume, may cause FT4 to drop progressively and by nega-
tive feedback, regulate the pituitary to produce more TSH 
to stimulate the thyroid [24]. The progressive increase in 
TSH during gestation may also reflect a stimulated thyroid 
state related to the relatively low iodine status of our popu-
lation [24]. Se treatment had no effect on these changes.
By contrast, in the Thy-Ab+ve group, where TSH was sig-
nificantly higher, TSH did not increase in women on placebo 
and indeed tended to decrease in women on Se. The lack of 
increase in women on placebo reflects the immunosuppres-
sion associated with tolerance of the fetal allograft [26]. 
This immune-suppressed state can reduce autoimmunity 
and decrease the Thy-Ab concentration, as observed in our 
study, preventing an increase in TSH in Thy-Ab+ve women 
[19, 27]. The finding that TSH decreased more in the Se 
group (P = 0.050) than in the placebo group suggests that Se 
supplementation may have an additive effect on the natural 
downsizing of the immune response, at least in TPO-Ab+ve 
women. This can be understood by the potential of Se sup-
plementation to reduce inflammation and modulate the 
immune response [7, 28]; Se may increase the number of 
regulatory T cells that can aid immune tolerance [29]. The 
fact that TSH did increase slightly in women on placebo 
toward the end of gestation (despite increasing immunosup-
pression) might also be explained by iodine deficiency or by 
the increasing uptake of Se by the placenta in late pregnancy 
[14, 22], resulting in an inadequate amount of Se remaining 
for the protection of the thyroid. However, at all assessments, 
TSH remained significantly higher in the TPO-Ab+ve group 
compared to the TPO-Ab−ve group.
FT4 declined significantly throughout gestation in all 
participants regardless of thyroid antibody status or treat-
ment. However, FT4 dropped significantly more in Thy-
Ab+ve women on Se than in those on placebo. We suggest 
that this may simply be a reflection of the lower TSH in the 
Se-treated TPO-Ab+ve group that resulted in lower stimula-
tion of FT4 production in the thyroid.
Our study has a number of limitations. It was not 
designed to look at the effect of Se supplementation on thy-
roid function so these data result from secondary analyses. 
The main other limitation is the low sample size, which 
may have limited our power to detect significant differ-
ences. The strength of our study is that none of the women 
was being treated with LT4 (thyroid function is not rou-
tinely screened in pregnancy in the UK), which allowed 
us to observe the natural evolution of thyroid function and 
the effect of Se supplementation on TH in pregnant women 
with mild-to-moderate iodine deficiency.
As maternal T4 is essential for fetal development, further 
investigation is needed to confirm our findings and evalu-
ate whether the higher FT4 drop in Thy-Ab+ve women with 
mild-to-moderate iodine deficiency supplemented with Se is 
detrimental or whether it is compensated for by the decrease 
in TSH.
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